文献速递甲状腺疾病

2025版ATA甲状腺乳头状癌风险分层系统在真实世界队列中的验证

Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该回顾性观察研究纳入670例甲状腺乳头状癌患者,评估2025版ATA风险分层系统相较于2015版的重新分布及对最终疾病结局预测的影响。结果显示2025版使低危比例下降22.2%,中危和高危分别增加41.7%和14.9%,新定义的「低-中危」类结构性疾病持续风险介于2015版低危和中危之间。

要点

  • 2025版ATA分层使低危比例降22.2%,中危和高危分别增41.7%和14.9%。
  • 新「低-中危」类结构性疾病持续风险高于2015低危(P=.003),低于2015中危(P=.012)。
  • 2025版低危和高危类的结构性疾病持续率与2015版对应类可比。

核心结论

  • 2025版ATA风险分层在真实世界中导致患者向更高风险类别迁移。
  • 新定义的低-中危类是唯一与2015版分层显著不同的类别,其结构性疾病持续风险介于既往低危和中危之间。

研究设计与样本

  • 回顾性观察研究,纳入670例具有完整组织病理学和最终疾病结局的甲状腺乳头状癌患者,来自三级医疗中心。

主要发现

  • 按2025版ATA分层重新分类后,低危甲状腺乳头状癌比例下降22.2%,中危和高危分别增加41.7%和14.9%。
  • 2025版低危和高危类的结构性疾病持续率与2015版对应类相当。
  • 2025版中-高危类与2015版中危类相似。
  • 2025版低-中危类结构性疾病持续风险高于2015版低危类(P = .003),低于2015版中危类(P = .012)。

临床怎么用

  • 临床采用2025版ATA分层时需注意低-中危类为新增类别,其结构性疾病持续风险介于既往低危和中危之间。
  • 对新定义的低-中危患者群体,需开展专门的前瞻性研究以明确恰当的管理策略。

局限性

  • 回顾性观察研究设计。
  • 单中心三级医疗中心数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting. DESIGN: Retrospective observational study. SETTING: Tertiary care center. PATIENTS: Data from 670 PTC patients with complete histopathological and final disease outcome were included. MAIN OUTCOME MEASURES: We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction. RESULTS: The reclassification according to the 2025 ATA risk stratification showed that the proportion of "low-risk" PTC decreased by 22.2%, while "intermediate-risk" and "high-risk" PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the 2 stratification systems revealed that structural disease persistence in the 2025 "low-risk" and "high-risk" classes was comparable. The 2025 "intermediate-high-risk" class was similar to the former "intermediate-risk" class, whereas the "low-intermediate-risk" class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 "low-risk" class (P = .003), but lower than that of the 2015 "intermediate-risk" class (P = .012). CONCLUSION: In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined "low-intermediate-risk" class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior "low-risk" and "intermediate-risk" classes, highlighting the need for dedicated prospective studies to address proper management of this newly defined group of patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Moneta C, Trevisan M, Colombo C, et al. Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2026. PMID: 41994857. doi:10.1210/clinem/dgag167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。